Immunic Inc Financials
This page shows Immunic Inc (IMUX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Recurring research burn is being sustained by external financing, with each capital raise mostly refilling rather than strengthening liquidity.
Across FY2024-FY2025, financing inflows of$140.1M offset most of$171.0M of free-cash burn. Because that gap still drained liquidity, cash ended FY2025 at$15.5M and equity slipped to-$6.7M , showing new capital is mainly replacing consumed cash runway rather than building a reserve.
Reported losses are close to actual cash outflow: FY2025 net loss was
Program spending has been remarkably steady: R&D was
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Immunic Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Immunic Inc carries a low D/E ratio of -4.60, meaning only $-4.60 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.
Immunic Inc's current ratio of 0.75 is below the typical benchmark, resulting in a score of 10/100. However, the company holds substantial cash reserves (51% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Immunic Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Immunic Inc generates $0.88 in operating cash flow (-$85.8M OCF vs -$97.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Immunic Inc's EBITDA was -$103.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5.3% from the prior year.
Immunic Inc reported -$97.2M in net income in fiscal year 2025. This represents an increase of 3.3% from the prior year.
Immunic Inc earned $-0.62 per diluted share (EPS) in fiscal year 2025. This represents an increase of 38.0% from the prior year.
Cash & Balance Sheet
Immunic Inc generated -$86.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 1.1% from the prior year.
Immunic Inc held $15.5M in cash against $0 in long-term debt as of fiscal year 2025.
Immunic Inc paid $0.00 per share in dividends in fiscal year 2025.
Immunic Inc had 12M shares outstanding in fiscal year 2025. This represents a decrease of 86.6% from the prior year.
Margins & Returns
Capital Allocation
Immunic Inc invested $82.0M in research and development in fiscal year 2025. This represents an increase of 2.4% from the prior year.
Immunic Inc invested $161K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 39.0% from the prior year.
IMUX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $25.6M | N/A | $20.0M-6.4% | $21.4M-0.8% | $21.5M | N/A | $21.4M+16.6% | $18.3M |
| SG&A Expenses | $7.6M | N/A | $6.0M+4.7% | $5.7M+8.0% | $5.3M | N/A | $4.4M-3.0% | $4.5M |
| Operating Income | -$33.2M | N/A | -$26.0M+4.0% | -$27.1M-1.0% | -$26.8M | N/A | -$25.7M-12.8% | -$22.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$32.6M | N/A | -$25.6M+4.6% | -$26.8M-5.3% | -$25.5M | N/A | -$24.4M-14.0% | -$21.4M |
| EPS (Diluted) | $-1.08 | N/A | $-0.13+35.0% | $-0.20+92.0% | $-2.51 | N/A | $-0.24-14.3% | $-0.21 |
IMUX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $189.7M+688.9% | $24.1M-40.9% | $40.7M-33.7% | $61.4M+199.4% | $20.5M-49.8% | $40.9M-36.9% | $64.8M-25.1% | $86.5M |
| Current Assets | $188.8M+725.4% | $22.9M-41.8% | $39.3M-34.4% | $59.8M+215.4% | $19.0M-51.8% | $39.3M-37.8% | $63.3M-25.6% | $85.0M |
| Cash & Equivalents | $186.6M+1105.4% | $15.5M-55.9% | $35.1M-36.5% | $55.3M+286.7% | $14.3M-59.9% | $35.7M-39.6% | $59.1M-25.9% | $79.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $38.5M+25.3% | $30.7M+1.7% | $30.2M+9.8% | $27.5M+6.7% | $25.8M+15.0% | $22.4M-4.7% | $23.5M+2.7% | $22.9M |
| Current Liabilities | $38.4M+25.3% | $30.6M+1.8% | $30.1M+10.1% | $27.3M+6.7% | $25.6M+15.4% | $22.2M-5.1% | $23.4M+3.0% | $22.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $151.2M+2366.3% | -$6.7M-163.6% | $10.5M-69.0% | $33.9M+741.4% | -$5.3M-128.7% | $18.4M-55.3% | $41.2M-35.2% | $63.6M |
| Retained Earnings | -$641.2M-5.4% | -$608.6M-3.3% | -$589.3M-4.5% | -$563.7M-5.0% | -$536.9M-5.0% | -$511.4M-5.2% | -$486.2M-5.3% | -$461.9M |
IMUX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.3M+10.3% | -$19.3M+4.3% | -$20.1M+18.2% | -$24.6M-13.0% | -$21.8M+5.2% | -$23.0M-10.4% | -$20.8M-22.0% | -$17.0M |
| Capital Expenditures | $2K-81.8% | $11K-83.6% | $67K+86.1% | $36K-23.4% | $47K+1466.7% | $3K-94.0% | $50K-72.2% | $180K |
| Free Cash Flow | -$17.3M+10.3% | -$19.3M+4.5% | -$20.2M+18.0% | -$24.6M-12.9% | -$21.8M+5.0% | -$23.0M-10.2% | -$20.8M-21.1% | -$17.2M |
| Investing Cash Flow | -$2K+81.8% | -$11K+83.6% | -$67K-86.1% | -$36K+23.4% | -$47K-1466.7% | -$3K+94.0% | -$50K+72.2% | -$180K |
| Financing Cash Flow | $188.6M+319632.2% | $59K | $0-100.0% | $65.5M | $0-100.0% | $77K | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IMUX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -21.6% | N/A | -243.6%-164.5pp | -79.1% | N/A | N/A | -59.1%-25.5pp | -33.6% |
| Return on Assets | -17.2% | N/A | -62.8%-19.2pp | -43.7%+80.5pp | -124.2% | N/A | -37.6%-12.9pp | -24.7% |
| Current Ratio | 4.92+4.2 | 0.75-0.6 | 1.31-0.9 | 2.19+1.4 | 0.74-1.0 | 1.77-0.9 | 2.71-1.0 | 3.75 |
| Debt-to-Equity | 0.25+4.9 | -4.60-7.5 | 2.88+2.1 | 0.81+5.7 | -4.88-6.1 | 1.22+0.6 | 0.57+0.2 | 0.36 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.75), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Immunic Inc profitable?
No, Immunic Inc (IMUX) reported a net income of -$97.2M in fiscal year 2025.
What is Immunic Inc's EBITDA?
Immunic Inc (IMUX) had EBITDA of -$103.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Immunic Inc's free cash flow?
Immunic Inc (IMUX) generated -$86.0M in free cash flow during fiscal year 2025. This represents a -1.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Immunic Inc's operating cash flow?
Immunic Inc (IMUX) generated -$85.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Immunic Inc's total assets?
Immunic Inc (IMUX) had $24.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Immunic Inc's capital expenditures?
Immunic Inc (IMUX) invested $161K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Immunic Inc spend on research and development?
Immunic Inc (IMUX) invested $82.0M in research and development during fiscal year 2025.
What is Immunic Inc's current ratio?
Immunic Inc (IMUX) had a current ratio of 0.75 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Immunic Inc's debt-to-equity ratio?
Immunic Inc (IMUX) had a debt-to-equity ratio of -4.60 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Immunic Inc's return on assets (ROA)?
Immunic Inc (IMUX) had a return on assets of -404.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Immunic Inc's cash runway?
Based on fiscal year 2025 data, Immunic Inc (IMUX) had $15.5M in cash against an annual operating cash burn of $85.8M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Immunic Inc's debt-to-equity ratio negative or unusual?
Immunic Inc (IMUX) has negative shareholder equity of -$6.7M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Immunic Inc's Piotroski F-Score?
Immunic Inc (IMUX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Immunic Inc's earnings high quality?
Immunic Inc (IMUX) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Immunic Inc?
Immunic Inc (IMUX) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.